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,Methods and Materials 
 
 
1H NMR and 13C NMR spectra were recorded on Bruker DPX-400 (operating at 400 MHz for 
1H NMR and 100 MHz for 13C NMR) in CDCl3 with tetramethylsilane as internal standard. 
All spectra were recorded at 25 oC and coupling constants (J values) were given in Hz. 
Chemical shifts were given in parts per million (ppm). Splitting patterns are designated as s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and p (pentet). All the 13C spectra 
were recorded with simultaneous decoupling of proton nuclei. Mass spectra were recorded on 
Agilent Technologies 6530 Accurate-Mass Q-TOF LC/MS. Absorption spectra were 
performed by using a Varian Cary-100 spectrophotometer. Fluorescence measurements were 
conducted on a Varian Eclipse spectrofluometer. Reactions were monitored by thin layer 
chromatography using Merck TLC Silica gel 60 F254. Silica gel column chromatography was 
performed over Merck Silica gel 60 (particle size: 0.040-0.063 mm, 230-400 mesh ASTM). 
All other reagents and solvents were purchased from Aldrich and used without further 
purification.  Compounds 11, 22, 53, Cu-catalyst4 and DPA-Bod dye5 were synthesized 
according to literature. 
Isothermal titration calorimetry experiments were performed on a iTC-200 microcalorimeter 
(Microcal Inc., Northampton, MA). All solutions were prepared in spectroscopic grade 
MeCN. For a typical ITC run, the instrument chamber (200 μL) contained a solution of a 
ligand (0.9 mM) while a 5.0 mM solution of Zn(OTf)2 was taken up in a 40 μL injection 
syringe. The syringe was assembled into the chamber for equilibration while stirring at 500 
rpm. The chamber temperature was set to 25 °C. The injections were programmed at 1 μL 
each, added over 2 sec and spaced 2 min apart. Association enthalpy (∆H° in cal/mol), 
“number of sites” (N), and association constant (K in M-1) were obtained by fitting the 
titration data using the “One (Two) Set of Sites model” algorithm provided in the MicroCal 
Origin Software package (version 7.0). Association entropy (∆S in cal/mol/K) is calculated 
from fitted values of ∆Ho and K. 
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Target Compounds 
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Synthetic Pathway: Numbering of molecules in this document (SI) is different from 
the article text. 
 
Synthesis of Compound 11 
 
ClClHS OH S S
HO OH
(1)
NaOH
C2H5OH
 
3-mercaptopropanol (1.85 g, 0.02 mol) and NaOH (0.8 g, 0.02 mol) were dissolved in ethanol 
(10 mL) was stirred at 0 °C for 30 min. Solution of cis-1,2-dichloroethylene (1 g, 0.01 mol) in 
EtOH (2 mL) was added dropwise and the reaction mixture was heated at 80 °C for 18 h. 
Then, it was extracted with diethyl ether and water. Organic layer was dried with Na2SO4 and 
evaporated in vacuo. The crude product was purified by silica gel column chromatography 
using n-hexane- ethyl acetate (1:4) as mobile phase. Fraction containing compound 1 was 
collected then the solvent was removed under reduced pressure (7.2 mmol 1.5 g, 72 %). 
 
1H NMR (400 MHz, Chloroform-d) δH  6.1 (s, 2H), 3.8 (t, J = 6.0 Hz, 4H), 2.8 (t, J = 7.0 Hz, 
4H), 2.3 (s, 2H), 1.9 (tt, J = 7.0, 6.0 Hz, 4H) ppm. 
13C NMR (100 MHz, CDCl3) δC 123.9, 60.9, 32.6, 30.8 ppm. 
 
 
 
Synthesis of Compound 21 
 
S S
TsO OTs
S S
HO OH
TsCl
(1) (2)
Et3N
CH2Cl2
 
 
S4 
 
Compound 1 (750 mg, 3.61 mmol) was dissolved in CH2Cl2 (15 mL) in 100 mL round-
bottomed flask. After reducing the temperature of the reaction mixture to 0 oC, triethylamine 
(1.5 mL, 10.8 mmol) and solution of p-toluene sulfonyl chloride (2 g, 10.8 mmol) in CH2Cl2 
(5 mL) was added dropwise. The reaction mixture was stirred for 12 h at room temperature. 
After the extraction with water, organic layer was dried with Na2SO4 and evaporated in 
vacuo. The crude product was purified by silica gel column chromatography using n-hexane- 
ethyl acetate (1:1) as mobile phase. Fraction containing compound 2 was collected then the 
solvent was removed under reduced pressure (2.7 mmol, 1.4 g, 75 %). 
 
1H NMR (400 MHz, Chloroform-d) δH 7.8 (d, J = 8.3 Hz, 4H), 7.4 (d, J = 8.1 Hz, 4H), 5.9 (s, 
2H), 4.2 (t, J = 5.9 Hz, 4H), 2.8 (t, J = 6.9 Hz, 4H), 2.5 (s, 6H), 1.9 (m, 4H) ppm. 
13C NMR (100 MHz, CDCl3) δC 144.9, 132.9, 129.9, 127.9, 123.9, 68.3, 29.9, 29.6, 21.7 ppm. 
 
 
 
 
Synthesis of Compound 3 
 
 
NH
N
H2N
N
Br
(3)
CH3CN
K2CO3
 
2-picolylamine (1.2 mL, 12 mmol) and K2CO3 (1.6 g, 12 mmol) were dissolved in CH3CN (10 
mL) was stirred for 10 min. Solution of propargyl bromide (0.7g, 6 mmol) in CH3CN (50 mL) 
was added dropwise and the reaction mixture was stirred for 12 h at room temperature. Then, 
the reaction mixture was filtered and the CH3CN was evaporated in vacuo. The crude product 
was purified by silica gel column chromatography using CH2Cl2:CH3OH:Et3N (100:5:1) as 
mobile phase. Fraction containing compound 3 was collected then the solvent was removed 
under reduced pressure (3.1 mmol, 450 mg, 41 %). 
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1H NMR (400 MHz, Chloroform-d) δH 8.5 (d, J = 3.9 Hz, 1H), 7.6 (td, J = 7.7, 1.8 Hz, 1H), 
7.3 (d, J = 8.4 Hz, 1H), 7.1 (dd, J = 7.5, 4.9 Hz, 1H), 3.9 (s, 2H), 3.4 (s, 2H), 2.3 (s, 1H), 2.2 
(t, J = 2.4 Hz, 1H) ppm. 
13C NMR (100 MHz, CDCl3) δC 158.9, 149.3, 136.4, 122.4, 122.0, 81.7, 71.7, 53.5, 37.7 ppm. 
HRMS (TOF - ESI): m/z calcd for C9H10N2+ 146.0844 [M+], Found: 147.08976 [M+H]+, ∆= 
13.02 ppm. 
 
Synthesis of Compound 4 
 
 
S S
TsO OTs
(2) CH3CN
K2CO3
NH
N
S S
N N
N N
(3)
(4)  
Compound 2 (600 mg, 1.16 mmol) were dissolved in CH3CN (20 mL) in a 100 mL round-
bottomed flask. Compound 3 (375 mg, 2.56 mmol) and K2CO3 (450 mg, 4.65 mmol) were 
added to the reaction mixture and the reaction mixture was refluxed for 18 h. Then, the 
reaction mixture was filtered and the CH3CN was evaporated in vacuo. The crude product was 
purified by silica gel column chromatography using CH2Cl2:CH3OH:Et3N (100:5:1) as mobile 
phase. Fraction containing compound 4 was collected then the solvent was removed under 
reduced pressure (0.65 mmol, 300 mg, 56 %). 
 
1H NMR (400 MHz, Chloroform-d) δH 8.5 (m, 2H), 7.6 (td, J = 7.6, 1.8 Hz, 2H), 7.4 (d, J = 
7.7 Hz, 2H), 7.1 (m, 2H), 6.0 (s, 2H), 3.8 (s, 4H), 3.4 (d, J = 2.4 Hz, 4H), 2.7 (t, J = 7.3 Hz, 
4H), 2.6 (t, J = 6.9 Hz, 4H), 2.2 (t, J = 2.3 Hz, 2H), 1.8 (p, J = 7.1 Hz, 4H) ppm. 
13C NMR (100 MHz, CDCl3) δC 158.9, 149.3, 136.4, 123.5, 123.0, 122.1, 78.3, 73.3, 59.7, 
51.9, 42.2, 31.9, 28.1 ppm. 
HRMS (TOF - ESI): m/z calcd for C26H32N4S2+ 464.2068 [M+], Found: 465.2094 [M+H]+, 
∆= 10.07 ppm. 
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Synthesis of Compound 6 
 
H
N
N
B
N
FF
(6)
CH2Cl2 ,
 
TFA
Et3N
BF3
.OEt2
O
p-chloranil
CHO
O N3
N3
(5)
 
 
CH2Cl2 (300 mL) was purged with Ar for 30 min. 2,4-dimethyl pyrrole (0.46 g, 4.8 mmol) 
and compound 52 (0.55 g, 2.2 mmol) were added. The color of the solution turned into red 
after the addition of 3 drops of trifluoroacetic acid. The reaction mixture was stirred at room 
temperature for 12h. Then, p-chloranil (0.54 g, 2.2 mmol) was added and the reaction mixture 
was stirred at room temperature for 45 min. Then triethyl amine (6 mL) and boron trifluoride 
diethyl etherate (6 mL) were added sequencially. After stirring at room temperature for 30 
min, it was extracted with water. Organic layer was dried with Na2SO4 and evaporated under 
reduced pressure. The crude product was purified by silica gel column chromatography using 
n-hexane-CH2Cl2 (1:2) as mobile phase. Fraction containing compound 6 was collected then 
the solvent was removed under reduced pressure (0.67 mmol, 305 mg, 53 %). 
1H NMR (400 MHz, Chloroform-d) δH 7.1 (d, J = 8.3 Hz, 2H), 6.9 (d, J = 8.3 Hz, 2H), 5.9 (s, 
2H), 3.9 (t, J = 6.4 Hz, 2H), 3.2 (t, J = 6.8 Hz, 2H), 2.5 (s, 6H), 1.8 – 1.7 (m, 2H), 1.6 (p, J = 
7.0 Hz, 2H), 1.5 – 1.4 (m, 4H), 1.4 (s, 6H) ppm. 
13C NMR (100 MHz, CDCl3) δC 159.6, 155.2, 143.1, 141.9, 131.8, 129.2, 126.9, 121.07, 
115.0, 67.9, 51.4, 29.1, 28.8, 26.6, 25.7, 14.6, 14.6 ppm. 
HRMS (TOF - ESI): m/z calcd for C25H30BF2N5O+ 465.34641 [M+], Found: 466.25188 
[M+H]+, ∆= 16.21 ppm. 
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Synthesis of Compound 7 
 
 
N
B
N
FF
(6)
O
NBS
CH2Cl2
DMF
(7)
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N
B
N
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O
N3
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Compound 6 (370 mg, 0.80 mmol) was dissolved in CH2Cl2:DMF (10:2 mL) was stirred for 
10 min. Solution of NBS (N-boromosuccinimide) (283 mg, 1.60 mmol) in CH2Cl2 (10 mL) 
was added dropwise and the reaction mixture was stirred for 2 h at room temperature. After 
the extraction with water, organic layer was dried with Na2SO4 and evaporated in vacuo. The 
crude product was purified by silica gel column chromatography using n-hexane-CH2Cl2 (1:1) 
as mobile phase. Fraction containing compound 7 was collected then the solvent was removed 
under reduced pressure (0.32 mmol, 200 mg, 40 %). 
 
 
1H NMR (400 MHz, Chloroform-d) δH 7.1 (d, J = 8.5 Hz, 2H), 7.0 (d, J = 8.5 Hz, 2H), 4.0 (t, 
J = 6.4 Hz, 2H), 3.3 (t, J = 6.8 Hz, 2H), 2.6 (s, 6H), ), 1.9 – 1.8 (m, 2H), 1.7-1.6 (m, 2H), 1.5 
– 1.4 (m, 4H), 1.4 (s, 6H). 
 
13C NMR (100 MHz, CDCl3) δC 160.1, 153.7, 142.4, 140.6, 130.8, 129.1, 126.2, 115.3, 
111.63, 68.0, 51.4, 29.7, 29.1, 28.8, 26.6, 25.7, 13.9, 13.6 ppm. 
 
HRMS (TOF - ESI): m/z calcd for C25H28BBr2F2N5O+ 619.06853 [M+], Found: 619.07808 
[M]+, ∆= -15.43 ppm. 
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Synthesis of Compound 8 
 
 
CHO
OCH3
N
B
N
FF
O
BrBr
OCH3 OCH3
benzene,
 
Dean-Stark
 
Reflux
AcOH,piperidine
N3
(7)
N
B
N
FF
O
N3
BrBr
(8)  
 
 
Compound 7 (110 mg, 0.18 mmol) and 4-methoxybenzaldehyde (61 mg, 0.44 mmol) were 
dissolved in benzene (30 mL). Piperidine (300µl) and acetic acid (300µl) were added. The 
reaction mixture was reflux using Dean-Stark apparatus until all aldehyde was consumed. 
Then, crude product was extracted with CH2Cl2 and water. Organic layer was dried with 
Na2SO4 and evaporated in vacuo. The crude product was purified by silica gel column 
chromatography using n-hexane-CH2Cl2 (1:2) as mobile phase. Fraction containing 
compound 8 was collected then the solvent was removed under reduced pressure (0.2 mmol, 
175 mg, 42 %). 
1H NMR (400 MHz, Chloroform-d) δH 8.1 (d, J = 16.6 Hz, 2H), 7.7 – 7.6 (m, 6H), 7.2 – 7.1 
(m, 2H), 7.1 – 7.0 (m, 2H), 6.9 (d, J = 8.8 Hz, 4H), 4.1 (t, J = 6.5 Hz, 2H), 3.9 (s, 6H), 3.3 (t, 
J = 6.9 Hz, 2H), 1.8-17 (m, 2H), 1.7 (q, J = 7.2 Hz, 2H), 1.6-1.5 (m,  4H), 1.5 (s, 6H). 
13C NMR (100 MHz, CDCl3) δC 160.8, 160.0, 148.4, 140.9, 139.1, 138.7, 132.4, 129.8, 129.6, 
129.3, 126.8, 116.2, 115.3, 114.3, 110.1, 67.9, 55.4, 51.4, 29.7, 29.1, 28.8, 26.6, 25.7, 13.9 
ppm. 
MS (TOF - Maldi): m/z calcd for C42H43BBr2F2N5O3+  874.4383 [M+], Found: 874.050 
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Synthesis of Compound 9 
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Compound 4 (12 mg, 0.026 mmol) and Compound 8 (50 mg, 0.057 mmol) were dissolved in 
CH2Cl2:methanol (5:1 mL). Flask was covered with aluminium folio to avoid light and Ar 
was purged 15 min. Triethylamine (100 µl) and Cu-catalyst4 (1 %, 0.3 mg) were added and 
the reaction mixture was stirred for 12 h at room temperature. After the extraction with water, 
organic layer was dried with Na2SO4 and evaporated in vacuo. The crude product was purified 
by silica gel column chromatography using CH2Cl2:methanol (100:8) as mobile phase. 
Fraction containing compound 9 was collected then the solvent was removed under reduced 
pressure (20 mg, 32 %). 
1H NMR (400 MHz, Chloroform-d) δH 8.6 – 8.5 (m, 2H), 8.1 (d, J = 16.6 Hz, 4H), 7.7 – 7.4 
(m, 16H), 7.5 (d, J = 7.9 Hz, 2H), 7.2 m, 6H), 7.1 – 7.0 (m, 4H), 7.0 – 6.9 (m, 8H), 6.0 (s, 
2H), 4.4 (t, J = 7.2 Hz, 4H), 4.0 (t, J = 6.3 Hz, 4H), 3.9 (s, 12H), 3.8 (s, 4H), 3.7 (s, 4H), 2.8 
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(t, J = 7.3 Hz, 4H), 2.7 (m, 4H), 2.6-2.5 (m, 4H), 2.0-1.9 (m, 4H),  1.9-1.8 (m, 4H), 1.6-1.5 
(m, 4H), 1.5 (s, 12H), 1.5 – 1.4 (m, 4H) ppm. 
13C NMR (100 MHz, CDCl3) δC 160.8, 159.9, 149.3, 149.08, 148.3, 143.9, 141.0, 1389.0, 
138.7, 136.5, 136.5, 132.4, 129.8, 129.6, 129.3, 126.8, 123.6, 123.3, 122.1, 116.1, 115.3, 
114.3, 110.0, 73.4, 67.9, 59.6, 55.4, 52.2, 50.2, 48.5, 42.2, 31.9, 30.3, 29.0, 26.4, 25.6, 13.9 
ppm. 
 
Synthesis of Compound 10 
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Compound 8 (50 mg, 0.057 mmol) and Compound 4 (265 mg, 0.57 mmol) were dissolved in 
CH2Cl2:methanol (5:1 mL). Flask was covered with aluminium folio to avoid light and Ar 
was purged 15 min. Triethylamine (100 µl) and Cu-catalyst4 (1 %, 3 mg) were added and the 
reaction mixture was stirred for 48 h at room temperature. After the extraction with water, 
organic layer was dried with Na2SO4 and evaporated in vacuo. The crude product was purified 
by silica gel column chromatography using CH2Cl2:methanol (100:4) as mobile phase. 
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Fraction containing compound 10 was collected then the solvent was removed under reduced 
pressure (30 mg, 40 %). 
1H NMR (400 MHz, Chloroform-d) δH 8.6 (m, 2H), 8.1 (d, J = 16.6 Hz, 2H), 7.7 – 7.6 (m, 
8H), 7.5 (d, J = 8.2, 1H), 7.4 (d, J = 7.9, 1H), 7.3 (s, 1H), 7.2 – 7.1 (m, 4H), 7.1– 7.0 (m, 2H), 
7.0 – 6.9 (m, 4H), 6.1 (s, 1H), 6.0 (s, 1H), 4.4 (t, J = 7.2 Hz, 2H), 4.0 (t, J = 6.3 Hz, 2H), 3.9 
(s, 6H), 3.8 (s, 4H), 3.4 (d, J = 2.4 Hz, 2H), 2.8 (td, J = 7.1, 5.8 Hz, 4H), 2.7 (t, J = 7.0 Hz, 
4H), 2.3 (t, J = 2.2 Hz, 1H), 2.0 – 1.9 (m, 2H), 1.9 – 1.8 (m, 8H), 1.7 – 1.5 (m, 2H), 1.5 (s, 
6H), 1.4 (m, 2H). 
13C NMR (100 MHz, CDCl3) δC 160.7, 159.9, 158.9, 149.3, 149.1, 148.3, 140.9, 138.9, 138.7, 
136.6, 136.5, 132.4, 129.8, 129.6, 129.3, 129.1, 128.2, 126.8, 123.1, 122.1, 116.1, 115.2, 
114.3, 110.0, 78.3, 73.4, 73.3, 67.9, 59.8, 59.7, 55.4, 52.0, 50.2, 48.5, 42.2, 31.9, 30.2, 29.7, 
29.1, 28.2, 26.4, 25.6, 13.9 ppm. 
 
 
Synthesis of Compound 11 
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Dean-Stark
 
Reflux
AcOH,piperidine
(6)
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Compound 6 (125 mg, 0.27 mmol) and 4-methoxybenzaldehyde (36 mg, 0.24 mmol) were 
dissolved in benzene (50 mL). Piperidine (150µl) and acetic acid (150µl) were added. The 
reaction mixture was reflux using Dean-Stark apparatus until all aldehyde was consumed. 
Then, crude product was extracted with CH2Cl2 and water. Organic layer was dried with 
Na2SO4 and evaporated in vacuo. The crude product was purified by silica gel column 
chromatography using n-hexane-CH2Cl2 (1:3) as mobile phase. Fraction containing 
compound 11 was collected then the solvent was removed under reduced pressure (40 mg, 25 
%). 
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1H NMR (400 MHz, Chloroform-d) δH 7.5 (d, J = 8.8 Hz, 2H), 7.3 (d, J = 14.4 Hz, 2H), 7.2 
(d, J = 8.5 Hz, 2H), 7.0 (d, J = 8.6 Hz, 2H), 6.7 (d, J = 8.7 Hz, 2H), 6.6 (s, 1H), 6.0 (s, 1H), 
4.0 (t, J = 6.4 Hz, 2H), 3.3 (t, J = 6.8 Hz, 2H), 3.0 (s, 6H), 2.6 (s, 3H), 1.9 – 1.8 (m, 2H), 1.7 
(p, J = 7.0 Hz, 2H), 1.6 – 1.5 (m, 4H), 1.50 (s, 3H), 1.46 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3) δC 159.5, 154.6, 152.7, 151.0, 142.9, 140.8, 139.1, 137.6, 133.5, 
130.6, 129.6, 129.2, 127.3, 124.7, 120.3, 117.6, 114.9, 114.5, 112.0, 67.8, 51.4, 40.2, 29.2, 
28.8, 26.6, 25.7, 14.9, 14.6, 14.5 ppm. 
HRMS (TOF - ESI): m/z calcd for C34H39BF2N6O+  596.3246 [M+], Found: 596.3250 [M]+, 
∆= -0.67 ppm. 
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Compound 10 (30 mg, 0.023 mmol) and Compound 11 (20 mg, 0.034 mmol) and were 
dissolved in CH2Cl2:methanol (5:1 mL). Flask was covered with aluminium folio to avoid 
light and Ar was purged 15 min. Triethylamine (100 µl) and Cu-catalyst4 (0.3 mg) were added 
and the reaction mixture was stirred for 48 h at room temperature. After the extraction with 
water, organic layer was dried with Na2SO4 and evaporated in vacuo. The crude product was 
purified by silica gel column chromatography using CH2Cl2:methanol (100:7) as mobile 
phase. Fraction containing compound 12 was collected then the solvent was removed under 
reduced pressure (23 mg, 53 %). 
1H NMR (400 MHz, Chloroform-d) δH 8.6 – 8.5 (m, 2H), 8.1 (d, J = 16.6 Hz, 2H), 7.7– 7.6 
(m, 9H), 7.5 – 7.4 (m, 6H), 7.3 (d, J = 16.7 Hz, 2H), 7.2 – 7.1 (m, 6H), 7.1 – 7.0 (m, 2H), 7.0-
6.9 (m, 6H), 6.7 (d, J = 8.4 Hz, 2H), 6.6 (s, 1H), 6.0 (s, 1H), 5.9 (s, 1H), 4.4 (q, J = 6.9 Hz, 
4H), 4.0 (m, 4H), 3.9 (s, 6H), 3.8 (s, 4H), 3.7 (s, 4H), 3.0 (s, 6H), 2.8 (t, J = 7.2 Hz, 4H), 2.7 
(d, J = 6.6 Hz, 4H), 2.6 (s, 4H), 2.0-1.8 (m, 12H), 1.6– 1.5 (m, 4H), 1.48 (s, 9H), 1.44 (s, 6H) 
ppm. 
13C NMR (100 MHz, CDCl3) δC 160.75, 159.95, 159.45, 154.64, 152.74, 151.03, 149.07, 
148.30, 142.86, 140.99, 140.81, 139.00, 138.72, 137.62, 136.54, 133.47, 132.40, 131.60, 
130.59, 129.79, 129.63, 129.57, 129.52, 129.26, 129.21, 129.10, 128.72, 128.23, 127.34, 
126.76, 124.66, 123.45, 123.29, 122.74, 122.12, 120.33, 117.58, 116.14, 115.25, 114.88, 
114.41, 114.31, 114.12, 112.01, 110.03, 67.87, 67.76, 59.66, 55.41, 54.30, 53.43, 52.15, 
50.16, 48.42, 40.23, 31.93, 30.26, 29.70, 29.08, 29.05, 27.84, 26.37, 26.33, 25.59, 14.94, 
14.59, 14.49, 13.96 ppm. 
 
 
 
 
 
 
 
 
S14 
 
Synthesis of the reference Compound 13 
 
 
Compound 4 (46.4 mg, 0.1 mmol) and Benzyl azide (29.3 mg, 0.22 mmol) were dissolved in 
CH2Cl2:Methanol (5:1 mL). Flask was covered with aluminium folio to avoid light and Ar 
was purged 15 min. Triethylamine (100 µl) and Cu-catalyst4 (1 %) were added and the 
reaction mixture was stirred for 12 h at room temperature. After the extraction with water, 
organic layer was dried with Na2SO4 and evaporated in vacuo. The crude product was purified 
by silica gel column chromatography using CH2Cl2:Methanol (93:7) as mobile phase. 
Fraction containing compound 13 was collected then the solvent was removed under reduced 
pressure (42 mg, 57 %). 
1H NMR (400 MHz, Chloroform-d) δH 8.5 (m, 2H), 7.6 (td, J = 7.6, 1.8 Hz, 2H), 7.43 (s, 2H), 
7.36 (d, J = 7.7 Hz, 2H), 7.3-7.2 (m, 6H), 7.2-7.1 (m, 4H) 7.1 (m, 2H), 6.0 (s, 2H), 5.5 (s, 4H),  
3.8 (s, 4H), 3.7 (s, 4H), 2.7 (t, J = 7.3 Hz, 4H), 2.6 (t, J = 6.9 Hz, 4H), 1.8 (p, J = 7.1 Hz, 4H) 
ppm. 
13C NMR (100 MHz, CDCl3) δC 159.3, 148.9, 144.8, 136.4, 134.9, 129.0, 128.6, 127.9, 123.1, 
122.8, 122.0, 59.8, 54.0, 52.2, 48.6, 31.9, 27.9 ppm. 
HRMS (TOF - ESI): m/z calcd for C40H46N10S2 [M+Na]+ 753.3241, Found: 753.3204 
[M+Na]+, ∆= 4.78 ppm. 
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Preparation of Zn complex of Compound 4 
 
S S
N N
N N
Zn2+
 
 
Zinc triflate (3.65 mg, 0.01 mmol) and Compound 4 (4.7 mg, 0.01 mmol) were dissolved in 
CH3CN (5 mL) and the reaction mixture was stirred for 12 hours at room temperature. 
HRMS (TOF - ESI): m/z calcd for C28H32F6N4O6S4Zn+ (with two counter ions, i.e., 2 triflates) 
826.040 [M+], Found: 827.0554 [M+H]+, ∆= -9.83 ppm. 
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Preparation of Zn complex of Compound 13. 
 
 
Zinc triflate (3.65 mg, 0.01 mmol) and Compound 13 (7.3 mg, 0.01 mmol) were dissolved in 
CH3CN (5 mL) and the reaction mixture was stirred for 1 hour at room temperature. 
HRMS (TOF - ESI): m/z calcd for C40H46N10S2Zn2+  397.1314 [M+2], Found: 397.1384 [M2+], 
∆= -17.42 ppm. 
 
 
S17 
 
Preparation of Zn Compound 1. 
Zinc triflate (0.74 mg, 0.002 mmol) and Compound 9 (4.4 mg, 0.002 mmol) were dissolved in 
CH2Cl2 (10 mL) and the reaction mixture was stirred for 12 hours at room temperature. 
 
Preparation of Zn Compound 2. 
Zinc triflate (0.74 mg, 0.002 mmol) and Compound 12 (3.9 mg, 0.002 mmol) were dissolved 
in CH2Cl2 (10 mL) and the reaction mixture was stirred for 12 hours at room temperature. 
 
Singlet Oxygen Measurements: 
Singlet oxygen quantum yields (φΔ) were calculated according to the literature.6 The relative 
quantum yields were calculated with reference to Methylene Blue (MB) in dichloromethane 
as 0.57.6b Air satutared DCM was obtained by bubbling air for 15 minutes. The absorbance of 
DPBF was adjusted around 1.0 in air saturated dichloromethane. Then, the photosensitizer (8) 
was added to cuvette and photosentizer’s absorbance was adjusted around 0.1 After, taking 
some measurements in dark, we exposed the cuvette to monochromatic light at the peak 
absorption wavelength for 3 minute. Absorbance was measured for several times after each 
irradiation. The graphics recorded are shown below; Figures 2 to 5. Then, slope of absorbance 
maxima of DPBF at 414 nm versus time graph for each photosensitizer were calculated. 
Singlet oxygen quantum yield were calculated according to the equation: 
φΔ (8) = φΔ (ref) ×[m (8)/m(ref)]×[F(ref)/F(8)]×[PF(ref)/PF(8)]  
where 8 and ref designate 'Compound 8' and 'Methylene Blue' respectively. m is the slope of 
difference in change in absorbance of DPBF (414 nm) with the irradiation time, F is the 
absorption correction factor, which is given by F = 1 – 10-OD(OD at the irradiation 
wavelength), and PF is absorbed photonic flux (μEinstein dm-3 s-1). 
φΔ (8) = φΔ (ref) ×[m (8)/m(ref)]×[F(ref)/F(8)]×[PF(ref)/PF(8)]  
φΔ (8) = 0.57 ×[-0.02905/-0.22956]×[1-10-0.1)/1-10-0.05]×[1)]  
φΔ (8) =0.14 
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Figure S1. Decrease in absorbance spectrum of trap molecule DBPF in the presence of  
compound 8 (3µM) in dichloromethane. (λex=660 nm, slit width=14-14, Xe-lamp) 
 
 
Figure S2. Absorbance decrease of DPBF at 414 nm with time in dichloromethane in the 
presence of compound 8. 
S19 
 
 
Figure S3. Decrease in absorbance spectrum of trap molecule DBPF in the presence of 
methylene blue (1µM) in dichloromethane. (λex=660 nm, slit width=14-14, Xe-lamp) 
 
 
 
Figure S4. Absorbance decrease of DPBF at 414 nm with time in dichloromethane in the 
presence of methylene blue (reference). 
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Figure S5. Fluorescence response of compound DPA-BOD upon uncaging of  Zn complex 1 
(5.0 µM each) recorded in acetonitrile. Initially DPA-BOD exhibits low fluorescence 
(quenched due to the active PET process), irradiation of the solution with the broadband 450 
W Xe-lamp (λ<550 nm is filtered) resulted in the photolysis of Zn complex 1 which can be 
followed by the enhanced emission spectrum of DPA-BOD (λex=490 nm, slit width=5-2.5). 
Highest intensity curve represent the maximum emission intensitie of DPA-BOD which was 
obtained by the addition of 1.0 equivalent of Zinc(II) cations in the form of triflate salt. 
(λex=490 nm, slit width=5-2.5). 
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Figure S6. Fluorescence response of compound DPA-BOD upon uncaging of  Zn complex 2 
(5.0 µM each) recorded in acetonitrile. Initially DPA-BOD exhibits low fluorescence 
(quenched due to the active PET process), irradiation of the solution with the broadband 450 
W Xe-lamp (λ<550 nm is filtered) resulted in the photolysis of Zn complex 2 which can be 
followed by the enhanced emission spectrum of DPA-BOD (λex=490 nm, slit width=5-2.5). 
Highest intensity curve represent the maximum emission intensitie of DPA-BOD which was 
obtained by the addition of 1.0 equivalent of Zinc(II) cations in the form of triflate salt. 
(λex=490 nm, slit width=5-2.5). 
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Figure S7. Fluorescence response of compound DPA-BOD upon uncaging of 1 equivalent 
Zn(II)-cage (5.0 µM each) recorded in acetonitrile. Initially compound DPA-BOD exhibits 
no fluorescence (quenched due to the active PET process), irradiation of the solution at 360 
nm resulted in the complete photolysis of Zn(II)-cage which can be followed by the enhanced 
emission spectrum of compound DPA-BOD. Highest intensity curve (purple)  represents the 
maximum emission intensity of DPA-BOD which were obtained by the addition of 1.0 
equivalent of Zinc(II) cations in the form of triflate salt.7 (λex=490 nm, slit width=5-2.5) 
 
 
 
Figure S8. Control experiment of DPA-BOD: Singlet oxygen generated from the irradiation 
of compound 8 does not change the fluorescence profile of Zn-DPA BOD complex.   
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Figure S9: 1H NMR spectrum of compound 1 (400 MHz, CDCl3) 
 
 
Figure S10: 13C NMR spectrum of compound 1 (100 MHz, CDCl3) 
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Figure S11: 1H NMR spectrum of compound 2 (400 MHz, CDCl3) 
 
 
Figure S12: 13C NMR spectrum of compound 2 (100 MHz, CDCl3 
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Figure S13: 1H NMR spectrum of compound 3 (400 MHz, CDCl3) 
 
 
Figure S14: 13C NMR spectrum of compound 3 (100 MHz, CDCl3) 
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Figure S15: Mass spectrum of compound 3 
 
 
 
 
Figure S16: 1H NMR spectrum of compound 4 (400 MHz, CDCl3) 
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Figure S17: 13C NMR spectrum of compound 4 (100 MHz, CDCl3) 
 
 
 
 
Figure S18: Mass spectrum of compound 4 
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                    Figure S19: 1H NMR spectrum of compound 6 (400 MHz, CDCl3) 
 
 
Figure S20: 13C NMR spectrum of compound 6 (100 MHz, CDCl3) 
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Figure S21: Mass spectrum of compound 6 
 
 
 
 
 
 
 
Figure S22: 1H NMR spectrum of compound 7 (400 MHz, CDCl3) 
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Figure S23: 13C NMR spectrum of compound 7 (100 MHz, CDCl3) 
 
 
 
 
                                               Figure S24: Mass spectrum of compound 7 
 
 
 
 
N
B
N
FF
O
N3
BrrBrr
N
B
N
FF
O
N3
BrrBrr
S32 
 
 
                    Figure S25: 1H NMR spectrum of compound 8 (400 MHz, CDCl3) 
 
 
Figure S26: 13C NMR spectrum of compound 8 (100 MHz, CDCl3) 
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Figure S27: Mass spectrum of compound 8 
 
 
 
                    Figure S28: 1H NMR spectrum of compound 9 (400 MHz, CDCl3) 
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Figure S29: 13C NMR spectrum of compound 9 (100 MHz, CDCl3) 
 
 
Figure S30: Mass spectrum of compound 9 
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                    Figure S31: 1H NMR spectrum of compound 10 (400 MHz, CDCl3) 
 
Figure S32: 13C NMR spectrum of compound 10 (100 MHz, CDCl3) 
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                    Figure S33: 1H NMR spectrum of compound 11 (400 MHz, CDCl3) 
 
 
Figure S34:  13C NMR spectrum of compound 11 (100 MHz, CDCl3) 
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Figure S35: Mass spectrum of compound 11 
 
 
 
Figure S36: 1H NMR spectrum of compound 12 (400 MHz, CDCl3) 
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Figure S37: 13C NMR spectrum of compound 12 (100 MHz, CDCl3) 
 
 
 
 
Figure S38: Mass spectrum of Zn complex of compound 4. m/z calcd for 
C28H32F6N4O6S4Zn+ (ditriflate salt) 826.040 [M+], Found: 827.0554 [M+H]+, ∆= -9.83 ppm. 
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Figure S39: 1H NMR spectrum of compound 13 (400 MHz, CDCl3) 
 
Figure S40: 13C NMR spectrum of compound 13 (100 MHz, CDCl3) 
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Figure S41: Mass spectrum of compound 13 (full spectrum), m/z calcd for C40H46N10S2 
[M+Na]+ 753.3241, ∆= 4.78 ppm.  
 
 
Figure S42: Mass spectrum of compound 13 (zoomed view), calcd for [M+Na]+ 753.3241 
 
 
 
Figure S43: Mass spectrum of compound 13 (zoomed view), m/z calcd for C40H46N10S2 
[M+H]+ 731.3421, ∆= 4.72 ppm. 
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Figure S44: Mass spectrum of Zn(II) complex of compound 13 (full spectrum), m/z calcd for 
C41H46F3N10O3S3Zn+ (monotriflate salt) 943.2160, ∆= 11.1 
 
 
 
 
Figure S45: Mass spectrum of Zn(II) complex of compound 13 (zoomed view), m/z calcd for 
C40H46N10S2Zn2+  397.1314 [M2+],  ∆= -17.42 ppm. 
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Figure S46.  The output of the 450 W Xe-lamp used in the photolysis experiments.  Red 
curve shows the filtered light output.  Total optical power is 85.5 W, and at 650 nm it is 
measured as 216 mW.  
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ITC Experiment: Titration of Compound 13 with Zn(II) triflate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S47. ITC titration curve of compound 13 in acetonitrile shows a clear 1-1 binding to 
Zn(II). Left: Final figure illustrating the titration of 0.9 mM compound 13 with 5.0 mM 
Zn(OTf)2, Right:  Thermodynamic parameters of interactions are summarized on the inset. 
 
 
 
